54 active not recruiting. 54 Phase 1, 22 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 54 | Active not recruiting 54 |
| Phase 2 | 22 | Active not recruiting 22 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma ABBV-291 - Non-Hodgkin's Lymphoma | Phase 1 | Active not recruiting | AbbVie | 21 | 2025-01-16 | 2026-09-29 |
| Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) SC262 - Non Hodgkin's Lymphoma, Large B-cell Lymphoma | Phase 1 | Active not recruiting | Sana Biotechnology | 6 | 2024-04-18 | 2025-11-28 |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas Tazemetostat Pill - Follicular Lymphoma, B-Cell Lymphoma | Phase 1 | Active not recruiting | Weill Medical College of Cornell University | 15 | 2023-10-04 | 2026-06-17 |
| Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) SC291 - Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | Sana Biotechnology | 16 | 2023-05-02 | 2025-10-02 |
| A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) ABBV-319 - Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | AbbVie | 39 | 2023-04-26 | 2026-08-28 |
| Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies SYNCAR-001, STK-009, Cyclophosphamide - CLL/SLL, NHL | Phase 1 | Active not recruiting | Synthekine | 36 | 2023-04-23 | 2026-07-10 |
| A Rollover Study of CC-122 CC-122, Dexamethasone - Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | Bristol-Myers Squibb | 12 | 2023-04-11 | 2026-05-11 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets ABBV-525 - Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | AbbVie | 78 | 2023-04-04 | 2026-05-04 |
| A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL MT-2111 - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Tanabe Pharma Corporation | 46 | 2023-01-30 | 2026-06-09 |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 33 | 2023-01-26 | 2026-10-30 |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma Mosunetuzumab - B Cell Lymphoma, Aggressive Lymphoma | Phase 1 | Active not recruiting | Washington University School of Medicine | 9 | 2022-12-22 | 2026-10-13 |
| Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas IMT-009, Fruquintinib - Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Immunitas Therapeutics | 67 | 2022-11-28 | 2025-10-16 |
| Study of Oral MRT-2359 in Selected Cancer Patients Oral MRT-2359 - NSCLC, SCLC | Phase 1 / Phase 2 | Active not recruiting | Monte Rosa Therapeutics, Inc | 174 | 2022-10-12 | 2026-03-03 |
| Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab Epcoritamab - Non-hodgkin Lymphoma | Phase 1 | Active not recruiting | Genmab | 17 | 2022-10-04 | 2026-09-11 |
| A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma JNJ-90014496 - Lymphoma, Non-Hodgkin, Lymphoma, B-Cell | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 166 | 2022-08-12 | 2026-11-03 |
| A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) GNC-038 - Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 12 | 2022-08-10 | 2025-09-26 |
| Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients Tafasitamab, Lenalidomide - Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Incyte Corporation | 53 | 2022-07-19 | 2026-01-16 |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma CD19-targeted chimeric antigen receptor T-cell - Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Pell Bio-Med Technology Co., Ltd. | 49 | 2022-05-31 | 2026-10-09 |
| Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone - Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Active not recruiting | Yazeed Sawalha | 38 | 2021-11-16 | 2026-07-02 |
Showing 20 of 54. Sign in to see all of them.
Lymphoma, Follicular (27) · Lymphoma, Mantle-Cell (18) · Lymphoma, Non-Hodgkin (17) · Lymphoma, B-Cell, Marginal Zone (15) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Lymphoma, B-Cell (13) · Burkitt Lymphoma (7) · Neoplasms (5) · Waldenstrom Macroglobulinemia (5) · Lymphoma (4) · Hodgkin Disease (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Dendritic Cell Sarcoma, Interdigitating (2)
Hemic and Lymphatic Diseases (54) · Immune System Diseases (53) · Immunoproliferative Disorders (53) · Lymphatic Diseases (53) · Lymphoproliferative Disorders (53) · Neoplasms by Histologic Type (53) · Lymphoma (50) · Neoplasms (49) · Lymphoma, B-Cell (41) · Lymphoma, Non-Hodgkin (37) · Hematologic Diseases (18) · Pathological Conditions, Signs and Symptoms (17) · Disease Attributes (16) · Pathologic Processes (16) · Chronic Disease (15)
Cyclophosphamide (15) · Rituximab (10) · Lenalidomide (8) · Prednisone (7) · Doxorubicin (6) · ibrutinib (6) · CT-P10 (5) · Vincristine (5) · Etoposide (4) · fludarabine phosphate (4) · polatuzumab vedotin (4) · Bendamustine Hydrochloride (3) · Gemcitabine (3) · Immunotherapy, Adoptive (3) · Magnetic Resonance Spectroscopy (3)
City of Hope Medical Center (6) · AbbVie (3) · Genmab (3) · National Cancer Institute (NCI) (3) · University of Washington (3) · Sana Biotechnology (2) · AIDS Malignancy Consortium (1) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1) · AstraZeneca (1) · Bambino Gesù Hospital and Research Institute (1) · Barbara Ann Karmanos Cancer Institute (1) · Beth Christian (1) · Bristol-Myers Squibb (1) · Catherine Bollard (1) · Dana-Farber Cancer Institute (1)
United States (46) · Australia (9) · Japan (8) · France (7) · Spain (7) · South Korea (6) · Israel (5) · Italy (5) · Canada (4) · Taiwan (4) · United Kingdom (4) · Belgium (3) · Czechia (3) · Germany (3) · Netherlands (3)
Alex F Herrera (2) · John Gerecitano, MD, PhD (2) · Mehrdad Abedi (2) · Ajay Gopal (1) · Alexey Danilov (1) · Alexey V Danilov (1) · Armin Ghobadi, M.D. (1) · Beth A Christian (1) · Beth Christian, MD (1) · Boyu Hu, MD (1) · Caitlin K Gribbin, M.D. (1) · Chen-Lung Lin, MD (1) · Christopher J Melani, M.D. (1)
PMID 34515338, PMID 25355819, PMID 27118452, PMID 32175617, PMID 33785483, PMID 34398557, PMID 34492703, PMID 34495306, PMID 34531588, PMID 36521030, PMID 36631449, PMID 37339586, PMID 37470137, PMID 37632592, PMID 37930156, PMID 39300447, PMID 39792928, PMID 39883889, PMID 40632620, PMID 40802906, PMID 40920572, PMID 41563911, PMID 41784015, PMID 42411504, PMID 42541678, PMID 42622258, PMID 42660129, PMID 42784255
2023 (3), P30CA033572 (2), P50CA107399 (2), 2019 (1), K24CA201524 (1), P30CA016058 (1), P30CA022453 (1), P30CA069533 (1), P30CA093373 (1), R01CA136907 (1), U01CA076576 (1), U01CA121947 (1), U01CA132123 (1), UL1TR002240 (1), UM1CA186644 (1)